ARIH1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P06245(ARIH1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The ARIH1 antibody is a research tool designed to detect and study the ARIH1 protein, also known as E3 ubiquitin-protein ligase ARIH1 or HHARI. ARIH1 is a member of the RING-between-RING (RBR) family of E3 ubiquitin ligases, which play critical roles in the ubiquitin-proteasome system by tagging specific substrate proteins for degradation. Structurally, ARIH1 contains a RING domain, a BRcat domain, and a UBA domain, enabling its interaction with E2 ubiquitin-conjugating enzymes and substrate recognition.

Biologically, ARIH1 is involved in diverse cellular processes, including mitophagy, innate immune signaling, and cell cycle regulation. It works in concert with Parkin (PARK2) to mediate the ubiquitination of mitochondrial proteins during stress-induced mitophagy, a pathway implicated in neurodegenerative diseases like Parkinson's. Additionally, ARIH1 modulates inflammatory responses by ubiquitinating antiviral signaling proteins such as MAVS and RIG-I. Dysregulation of ARIH1 has been linked to cancers, autoimmune disorders, and neurological conditions.

The ARIH1 antibody is widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to explore its expression, localization, and functional interactions. Researchers employ it to investigate ARIH1's role in disease mechanisms, therapeutic targeting, and its crosstalk with other ubiquitination pathways. Commercial ARIH1 antibodies are typically validated for specificity across human, mouse, and rat models, supporting both basic and translational studies.